Background

Hepatoblastoma, which accounts for the majority of pediatric liver cancers, shows a cure rate of around 80% when detected early through surgery and combination chemotherapy. The problem lies in high-risk pediatric patients who are refractory to cisplatin-based standard therapies or have developed distant metastases. Their 3-year survival rate without accidents is extremely poor, falling below 30%. Repeated cytotoxic chemotherapy often leaves systemic aftereffects in growing children, such as permanent hearing loss and cardiotoxicity. If multiple metastatic lesions remain, it is considered difficult to attempt even liver resection, let alone liver transplantation, which is a last resort.

Chimeric Antigen Receptor T-cell (CAR-T) therapy, which genetically recombines genes to attack tumors, has proven effective in hematologic malignancies such as leukemia. However, it has yet to achieve significant clinical success in solid tumors. This is due to the difficulty of identifying tumor-specific antigens and the barrier of the dense extracellular matrix that hinders immune cell infiltration. Inhibitory factors within the tumor microenvironment (TME), such as Transforming Growth Factor-beta (TGF-β), also impede the survival of cell therapies within the body. To save refractory pediatric patients, a new design capable of precisely targeting tumor antigens while breaking through the immunosuppressive environment was urgently needed.

Key Findings

Researchers focused on the Glypican-3 (GPC3) protein, which is specifically overexpressed on the surface of pediatric hepatoblastoma. GPC3 expression is extremely limited in the major organs of healthy adults and children, indicating a lower risk of on-target, off-tumor toxicity. The researchers took a basic scaffold combining a GPC3-recognizing single-chain variable fragment (scFv) with a 4-1BB costimulatory domain and added an immune-enhancing genetic circuit. To promote the in vivo proliferation and long-term survival of T-cells, they incorporated an Interleukin-15 (IL-15) expression cassette, while also integrating a dominant-negative TGF-β receptor type 2 (dnTGF-βRII) to neutralize the immune evasion signals of cancer cells.

This next-generation armored GPC3 CAR-T was administered to a 6-year-old patient with lung and peritoneal metastases following standard anticancer therapy. The protocol involved a single intravenous infusion of a dose of 1×10^6 cells per kg of patient body weight, followed by response tracking. Imaging performed at week 4 of infusion confirmed that the target lesion size decreased by 82% compared to baseline. Serum alpha-fetoprotein (AFP) levels also plummeted from 124,000 ng/mL before treatment to 8.4 ng/mL at week 12, settling within the normal range (less than 10 ng/mL).

Follow-up imaging showed that the tumor lesion signal had completely disappeared, resulting in a determination of Complete Response (CR). The therapeutic cells that proliferated within the patient reached peak concentration in the blood on day 14 of infusion and maintained high concentrations for over half a year. This is considered a breakthrough that overcomes the limitations of existing cell therapies, which typically die off within weeks inside solid tumors. In terms of safety, the treatment resulted only in mild Grade 1 fever, with no severe side effects of Grade 3 or higher.

Significance and Outlook

This is evaluated as having demonstrated, through patient administration data, that the therapeutic range of immune cell therapies can be expanded from hematologic malignancies to refractory pediatric solid tumors. The platform structure combining IL-15 and dnTGF-βRII holds the potential for wide application in designing treatments for other refractory solid tumors. This is progress that opens opportunities for a cure while reducing the systemic burden on pediatric patients for whom cytotoxic chemotherapy is difficult to administer.

Challenges to overcome before commercialization as a universal treatment are also clear. Since this is limited to a single patient case report, it is noted that the reproducibility of the therapeutic effect must be verified through multi-center clinical trials. It is also necessary to urgently establish a long-term follow-up system to monitor whether genetically modified cells that remain in the body for extended periods cause autoimmune diseases or transformation. Efforts to increase treatment accessibility by streamlining high production costs and complex manufacturing processes must follow.